Why Nektar Therapeutics (NKTR) Stock Is Up Today

NEW YORK (TheStreet) -- Nektar Therapeutics (NKTR) shares are up 9.8% to $12.13.

The rise follows an initiation of coverage with a "buy" rating and $15 price target by analysts at Jefferies Group (JEF).

The positive rating comes on speculation about the approval of the drug manufacturer's once a day opiod-induced constipation relieving pill, Naloxegol, which Jefferies believes could provide a major boost to the company's bottom line.

The FDA panel reviewing the drug is set to meet in mid-June.

Must Read: Warren Buffett's 10 Favorite Stocks

SELL NOW: If you own any of the 900 stocks that TheStreet Quant Ratings has identified as a 'Sell'...you could potentially lose EVERYTHING in the next 6-12 months. Learn more.

NKTR Chart

NKTR data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more. 

More from Markets

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2